Project Grant R43CA257133
Award Date 3/1/22
Completion Date 12/31/24
Dollars Obligated $796K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- This $692,491 Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop a non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The project will leverage the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial biospecimens to explore cancer-specific early epigenetic marks, specifically 5-hydroxymethylcytosines...
- Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded August 1, 2025, through July 31, 2028. The awardee will develop and validate LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test for detecting clinically actionable lung cancer mutations including EGFR, KRAS, ALK, MET, and...
- Federal Grant Award Summary Alelopharma Inc. received a $399,153 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded on July 9, 2025, with completion targeted for June 30, 2026. The company is developing an ultra-precision liquid biopsy diagnostic test to detect ALK (anaplastic lymphoma kinase) translocations in cell-free RNA from blood plasma of non-small cell lung cancer (NSCLC) patients. The diagnostic platform,...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded Beckman Research Institute of the City of Hope a $738,675 Cooperative Agreement on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an innovative exosome-based liquid biopsy assay for non-invasive early detection of colorectal adenomas and cancers. The project, extending through February 28, 2031, addresses a critical gap in current screening methodologies by creating...
- Federal Cooperative Agreement Summary The University of Texas MD Anderson Cancer Center received a $525,013 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective September 1, 2025, through August 31, 2030. This award supports the validation of blood-based biomarkers for lung cancer risk assessment among individuals with no smoking history, addressing a significant public health gap as lung cancer in...
- Federal Cooperative Agreement Award Summary The Beckman Research Institute of the City of Hope received a $690,637 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) beginning September 1, 2025, and concluding August 31, 2030. The award supports the development and validation of a blood-based biomarker test for early detection of pancreatic ductal adenocarcinoma (PDAC) that leverages 5-methylcytosine (5MC) and...
- Federal Project Grant Award Summary Nuvox Pharma, L.L.C. received a $1.84M Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded September 22, 2025, with completion targeted for August 31, 2027. The grant funds research into liquid biopsy—a non-invasive blood-based diagnostic approach—for glioblastoma (GBM) patients undergoing chemoradiation combined with dodecafluoropentane emulsion (DDFPE), an oxygen therapeutic...
- Federal Grant Award Summary Darwin Biosciences, Inc. received a $399,998 Project Grant award dated July 17, 2025, from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an innovative point-of-need lung cancer screening device for low-resource settings. The company is adapting its existing handheld diagnostic platform—previously developed under a $12 million Department of Defense contract for pathogen detection—to identify lung cancer...
- This $215,985 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University is for a pilot study to sequence exosomal RNA from the blood and urine of 50 patients with renal cell carcinoma. The objective is to identify early biomarkers for therapeutic response to the immune checkpoint inhibitor combination of nivolumab and ipilimumab. The study will analyze changes in the exosomal proteins and RNA,...